Q-omics provides the consensus-scored HNRNPA1P25 profile across patient tissues and cancer cell-line models. HNRNPA1P25 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, HNRNPA1P25 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, HNRNPA1P25 RNA expression shows 12,013 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, KIRC, and TGCT as cancer lineages where HNRNPA1P25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPA1P25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPA1P25 survival associations across molecular data types. HNRNPA1P25 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPA1P25 RNA expression–survival associations across cancer types. High HNRNPA1P25 expression shows unfavorable associations in LUAD, KICH and DLBC, but favorable associations in HNSC, PAAD and LAML. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify LUAD as the clearest survival context for HNRNPA1P25 RNA expression.
This table summarizes HNRNPA1P25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPA1P25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPA1P25 shows lower tumor expression in THCA and higher tumor expression in KIRC, COAD, HNSC, LIHC and STAD. The KIRC box plot shows higher HNRNPA1P25 RNA expression in tumor versus normal tissue (log2 FC = +0.046, t-test p < 0.001).
This table shows molecular features associated with HNRNPA1P25 in patient tissues and cancer cell lines. In patient samples, HNRNPA1P25 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
